---
title: 'Industry Daily Summary: What Happened on November 11, 2026'
headline: argenx agrees to buy Unnatural Products for up to $1.15 billion
description: CVS plans to separate its pharmacy and health businesses. Oura is planning
  a $625 million acquisition of Counsel Health.
url: https://thebench.bio/news/industry/2026-11-11
topic: industry
date: '2026-11-11'
covers:
- '2026-11-11'
date_published: '2026-11-11T12:04:24Z'
date_modified: '2026-11-12T00:04:07Z'
tags:
- Industry
- Funding
- Software
- Manufacturing
sources: 8
publisher: TheBench.Bio
---

# Industry Daily Summary: What Happened on November 11, 2026

**argenx agrees to buy Unnatural Products for up to $1.15 billion**

CVS plans to separate its pharmacy and health businesses. Oura is planning a $625 million acquisition of Counsel Health.

## Today in brief

argenx will pay $550 million upfront for Unnatural Products, with up to $595 million more tied to milestones. [1] CVS plans to create two publicly traded companies, splitting its retail pharmacy business from its health care businesses. [2] Oura is planning a $625 million deal for Counsel Health as wearable companies broaden their health care offerings. [3]

## argenx adds a peptide discovery platform in a deal worth up to $1.15 billion

argenx agreed to acquire Unnatural Products, whose platform combines machine-learning-assisted compound design with large-scale synthesis and screening. [1] [4] The deal includes $550 million upfront and up to $595 million in development and regulatory milestone payments. [1]

The acquisition would give argenx full ownership of a company in which it previously held a minority stake. [1] The companies expect to close by year-end, subject to customary conditions, and plan to keep Unnatural Products’ team at its Santa Cruz site. [1]

The companies began working together in July 2025 to discover oral or long-acting treatments for immune-mediated diseases. [1]

## CVS plans to separate its retail pharmacy from its health businesses

After a strategic review, CVS plans to form two publicly traded companies, with the separation expected in the first half of 2028, subject to approvals and other conditions. [2] A health care solutions company would retain Aetna, Caremark, CVS Specialty, Oak Street Health, and Signify Health. The other company would operate retail pharmacies and related services. [2]

The plan keeps the insurer and pharmacy benefit manager together while splitting off retail dispensing. [2] CVS said the separation could give each business more strategic focus and let the pharmacy company pursue broader commercial partnerships. [2]

CVS expanded across insurance, pharmacy benefits, and retail through acquisitions including Caremark in 2007 and Aetna in 2018. [2]

## Oura plans to buy Counsel Health for $625 million

Oura is planning to acquire Counsel Health in a deal valued at $625 million. [3] The planned acquisition comes as wearable companies broaden their health care offerings. [3]

## Also worth knowing

- AstraZeneca acquired Omniose, bringing its bacterial vaccine platform into the company’s infectious disease unit after a research collaboration that began in 2024. [5] [6]
- ProBio granted AbTis exclusive worldwide rights to a discovery-stage oncology antibody. AbTis plans to develop it as an antibody-drug conjugate using its site-specific conjugation technology. [7] [8]

## The day in numbers

- **$1.15 billion**: Maximum value of argenx’s planned acquisition of Unnatural Products, including up to $595 million in milestone payments. [1]
- **First half of 2028**: CVS’s expected timing for separating its pharmacy and health care businesses, subject to conditions and approvals. [2]
- **$625 million**: Reported value of Oura’s planned acquisition of Counsel Health. [3]

## Also published

- [Cut the Noise. Build Conviction: Turning Competitive Insights into Strategy and Implementation](<https://www.fiercepharma.com/resource/cut-noise-build-conviction-turning-competitive-insights-strategy-and-implementation>), Fierce Pharma
- [Patients not just at the table, but creating their own: In conversation with Donna Cryer](<https://pharmaphorum.com/patients/patients-not-just-table-creating-their-own-conversation-donna-cryer>), pharmaphorum
- [Executive Conversations: When Should Trade Teams Join Launch Planning?](<https://www.pharmaceuticalcommerce.com/view/executive-conversations-how-early-should-trade-join-launch-planning>), Pharmaceutical Commerce
- [Longevity sector ambitions outpace regulatory and investment frameworks](<https://www.pharmaceutical-technology.com/news/longevity-sector-ambitions-outpace-regulatory-and-investment-frameworks/>), Pharmaceutical Technology
- [Austria builds life sciences momentum](<https://european-biotechnology.com/sponsored-publications/austria-builds-life-sciences-momentum/>), European Biotechnology
- [The PM Awards aren’t just for agencies. They’re for the people who make great work happen](<https://pharmaphorum.com/partner-content/pm-awards-arent-just-agencies-theyre-people-who-make-great-work-happen>), pharmaphorum
- [OCT New England 2026: the next phase in China’s rise](<https://www.clinicaltrialsarena.com/features/oct-new-england-2026-the-next-phase-in-chinas-rise/>), Clinical Trials Arena
- [Weekly Tech+Bio #90: AI Momentum Moves Into Clinical Trials — Companies to Watch in 2026](<https://www.techlifesci.com/p/weekly-techbio-90-ai-momentum-moves>), Weekly Tech+Bio
- [Executive Conversations: Why Trade Strategy Has to Start Before Launch](<https://www.pharmaceuticalcommerce.com/view/executive-conversations-why-trade-strategy-has-to-start-before-launch>), Pharmaceutical Commerce
- [AstraZeneca Acquires Omniose, Adding Bioconjugate Vaccine Platform](<https://www.biopharminternational.com/view/astrazeneca-acquires-omniose-bioconjugate-vaccine-platform>), BioPharm International
- [AstraZeneca Acquires Omniose, Adding Bioconjugation Platform to Vaccine Pipeline](<https://www.pharmexec.com/view/astrazeneca-acquires-omniose-bioconjugation-platform>), Pharmaceutical Executive

## Sources

1. [Argenx Expands Immunology Capabilities with Up-to-$1.15B UNP Acquisition](<https://www.genengnews.com/topics/translational-medicine/argenx-expands-immunology-capabilities-with-up-to-1-15b-unp-acquisition/>), GEN, 2026-11-10
2. [CVS Health’s Breakup: A Turning Point for Pharma Supply Chains or a Redistribution of Market Power?](<https://www.pharmaceuticalcommerce.com/view/cvs-health-s-breakup-a-turning-point-for-pharma-supply-chains-or-a-redistribution-of-market-power->), Pharmaceutical Commerce, 2026-11-11
3. [Oura makes bet on AI in healthcare with $625M Counsel Health buy](<https://www.medtechdive.com/news/oura-makes-bet-on-ai-in-healthcare-with-625m-counsel-health-buy/874398/>), MedTech Dive, 2026-11-11
4. [The biotech bi-weekly: world-first AI biosecurity lab launched, a new streamlined multiomic imaging system, and new EV media and qPCR master mixes](<https://www.biotechniques.com/drug-discovery-development/the-biotech-bi-weekly-world-first-ai-biosecurity-lab-launched-a-new-streamlined-multiomic-imaging-system-and-new-ev-media-and-qpcr-master-mixes/>), BioTechniques, 2026-11-11
5. [AZ boosts vaccine capabilities with Omniose buy](<https://pharmaphorum.com/news/az-boosts-vaccine-capabilities-omniose-buy>), pharmaphorum, 2026-11-11
6. [AstraZeneca acquires bacterial vaccine biotech, Omniose ](<https://www.pharmaceutical-technology.com/news/astrazeneca-omniose-acquisition-bacterial-infection/>), Pharmaceutical Technology, 2026-11-11
7. [ProBio signs global antibody licensing deal with AbTis](<https://www.pharmaceutical-technology.com/news/probio-global-antibody-licensing-deal-abtis/>), Pharmaceutical Technology, 2026-11-11
8. [ProBio Licenses Oncology Antibody to AbTis for Site-Specific ADC](<https://www.biopharminternational.com/view/probio-licenses-oncology-antibody-abtis-site-specific-adc>), BioPharm International, 2026-11-11

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.genengnews.com/topics/translational-medicine/argenx-expands-immunology-capabilities-with-up-to-1-15b-unp-acquisition/>
[2]: <https://www.pharmaceuticalcommerce.com/view/cvs-health-s-breakup-a-turning-point-for-pharma-supply-chains-or-a-redistribution-of-market-power->
[3]: <https://www.medtechdive.com/news/oura-makes-bet-on-ai-in-healthcare-with-625m-counsel-health-buy/874398/>
[4]: <https://www.biotechniques.com/drug-discovery-development/the-biotech-bi-weekly-world-first-ai-biosecurity-lab-launched-a-new-streamlined-multiomic-imaging-system-and-new-ev-media-and-qpcr-master-mixes/>
[5]: <https://pharmaphorum.com/news/az-boosts-vaccine-capabilities-omniose-buy>
[6]: <https://www.pharmaceutical-technology.com/news/astrazeneca-omniose-acquisition-bacterial-infection/>
[7]: <https://www.pharmaceutical-technology.com/news/probio-global-antibody-licensing-deal-abtis/>
[8]: <https://www.biopharminternational.com/view/probio-licenses-oncology-antibody-abtis-site-specific-adc>
